Why Sanofi Is Buying a U.S. Cancer Biotech for Nearly 3 Times Its Market Value

French pharma giant Sanofi agreed to buy U.S. biotech company Synthorx Inc. for $2.5 billion, almost triple its market value, accelerating a push into cancer under new Chief Executive Officer Paul Hudson.

Sanofi will pay $68 a share in cash for Synthorx, the companies said Monday. Shares of the unprofitable San Diego-based company closed at $25.03 Friday, having surged 40% last week.

The deal underscores the Paris-based drugmaker’s efforts to build its portfolio of innovative therapies in the fast-growing and lucrative cancer field. It was unveiled a day before Hudson outlines his pipeline and acquisition priorities, along with his initial plans for the consumer-health, diabetes and other units. The purchase marks Sanofi’s first multibillion acquisition since early 2018.

Investors are counting on Hudson to fire up Sanofi’s research operations and step up the search for novel products to reduce its reliance on Dupixent, a standout medicine for severe eczema and asthma. Hudson, the former pharma head at Novartis AG, is credited with launching key medicines at his previous job before becoming CEO of Sanofi in September.

The purchase is the latest sign of big pharma’s increasing bet on oncology medicines with drugmakers including Roche Holding AG, Bristol-Myers Squibb Co. and Merck & Co. leading the pack. Big premiums have become the norm as companies place riskier bets on acquiring potentially lucrative treatments from biotech startups.

Other Deals

Another company in catch-up mode, GlaxoSmithKline Plc, paid about $5.1 billion early this year for Tesaro, the maker of a promising cancer medicine called Zejula. The U.K. drugmaker’s new CEO, Emma Walmsley, has doubled the number of experimental cancer drugs in human testing to 16. Three of those could reach the market next year.

Synthorx’s main drug, known as THOR-707, is being explored as a treatment for multiple types of solid tumors, together with immune checkpoint inhibitors and other future combinations.

Sanofi shares fell as much as 0.6% on Monday.

The French drugmaker earlier this year said it would accelerate 17 drug programs, almost half in cancer, and drop more than a dozen others under development. Analysts at HSBC wrote in August that more deals would be the fastest way to build up Sanofi’s stable of medicines and profile in cancer. Sanofi and partner Regeneron Pharmaceuticals Inc. won approval last year for an immune-oncology drug — Sanofi’s first — for a deadly form of skin cancer.

In another sign of rising deal activity in the biotech sector, Astellas Pharma Inc. last week agreed to buy Audentes Therapeutics Inc. for about $3 billion, paying a 110% premium to advance into the gene therapy realm.

Sanofi shares have climbed about 11% since Hudson was named CEO in June, closing at 83.56 euros on Friday. The stock had declined almost 16% over the previous four years.

Morgan Stanley advised Sanofi, which used Weil, Gotshal & Manges as its law firm. Synthorx’s advisers were Centerview Partners LLC and Cooley LLP.

More must-read stories from Fortune:

Want a SIM card in China? You’ll now need to get your face scanned first
2020 Crystal Ball: Predictions for the economy, politics, technology, and more
—In the wake of Brexit, Amsterdam is the new London
—The world’s third-richest man has a Donald Trump problem
—Why it’s still so hard to sell medical marijuana in Asia
Catch up with Data Sheet, Fortune’s daily digest on the business of tech.

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.